当前位置: 首页 >> 检索结果
501. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
作者: Gideon M Hirschfield.;Andrew Mason.;Velimir Luketic.;Keith Lindor.;Stuart C Gordon.;Marlyn Mayo.;Kris V Kowdley.;Catherine Vincent.;Henry C Bodhenheimer.;Albert Parés.;Michael Trauner.;Hanns-Ulrich Marschall.;Luciano Adorini.;Cathi Sciacca.;Tessa Beecher-Jones.;Erin Castelloe.;Olaf Böhm.;David Shapiro.
来源: Gastroenterology. 2015年148卷4期751-61.e8页
We evaluated the efficacy and safety of obeticholic acid (OCA, α-ethylchenodeoxycholic acid) in a randomized controlled trial of patients with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid therapy.
502. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy.
作者: Andres Acosta.;Michael Camilleri.;Andrea Shin.;Maria I Vazquez-Roque.;Johanna Iturrino.;Duane Burton.;Jessica O'Neill.;Deborah Eckert.;Alan R Zinsmeister.
来源: Gastroenterology. 2015年148卷3期537-546.e4页
Weight loss after pharmacotherapy varies greatly. We aimed to examine associations of quantitative gastrointestinal and psychological traits with obesity, and to validate the ability of these traits to predict responses of obese individuals to pharmacotherapy.
503. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.
作者: Radha K Dhiman.;Baldev Rana.;Swastik Agrawal.;Ashish Garg.;Madhu Chopra.;Kiran K Thumburu.;Amit Khattri.;Samir Malhotra.;Ajay Duseja.;Yogesh K Chawla.
来源: Gastroenterology. 2014年147卷6期1327-37.e3页
Little is known about whether probiotics can affect outcomes of patients with cirrhosis and hepatic encephalopathy (HE). We assessed the efficacy of a probiotic preparation in preventing the recurrence of HE (primary outcome) and reducing the number of hospitalizations and severity of liver disease in patients with cirrhosis.
504. Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial.
作者: John G Hunter.;Peter J Kahrilas.;Reginald C W Bell.;Erik B Wilson.;Karim S Trad.;James P Dolan.;Kyle A Perry.;Brant K Oelschlager.;Nathaniel J Soper.;Brad E Snyder.;Miguel A Burch.;William Scott Melvin.;Kevin M Reavis.;Daniel G Turgeon.;Eric S Hungness.;Brian S Diggs.
来源: Gastroenterology. 2015年148卷2期324-333.e5页
Transoral esophagogastric fundoplication (TF) can decrease or eliminate features of gastroesophageal reflux disease (GERD) in some patients whose symptoms persist despite proton pump inhibitor (PPI) therapy. We performed a prospective, sham-controlled trial to determine if TF reduced troublesome regurgitation to a greater extent than PPIs in patients with GERD.
505. Mucosal impedance discriminates GERD from non-GERD conditions.
作者: Fehmi Ates.;Elif Saritas Yuksel.;Tina Higginbotham.;James C Slaughter.;Jerry Mabary.;Robert T Kavitt.;C Gaelyn Garrett.;David Francis.;Michael F Vaezi.
来源: Gastroenterology. 2015年148卷2期334-43页
Current diagnostic tests for gastroesophageal reflux disease (GERD) are suboptimal and do not accurately and reliably measure chronicity of reflux. A minimally invasive device has been developed to assess esophageal mucosal impedance (MI) as a marker of chronic reflux. We performed a prospective longitudinal study to investigate MI patterns in patients with GERD and common nonreflux conditions, to assess MI patterns before and after treatment with proton pump inhibitors and to compare the performance of MI and wireless pH tests.
506. Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST).
作者: Renate Schmelz.;Martin Bornhäuser.;Johannes Schetelig.;Alexander Kiani.;Uwe Platzbecker.;Uta Schwanebeck.;Xina Grählert.;Lutz Uharek.;Daniela Aust.;Gustavo Baretton.;Rainer Schwerdtfeger.;Jochen Hampe.;Roland Greinwald.;Ralph Mueller.;Gerhard Ehninger.;Stephan Miehlke.
来源: BMC Gastroenterol. 2014年14卷197页
Gastrointestinal graft-versus-host disease (GvHD) is a potentially life-threatening complication after allogeneic stem cell transplantation (SCT). Since therapeutic options are still limited, a prophylactic approach seems to be warranted.
507. Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study.
作者: Philip B Miner.;Debra G Silberg.;Magnus Ruth.;Frank Miller.;John Pandolfino.
来源: BMC Gastroenterol. 2014年14卷188页
The γ-aminobutyric acid type B-receptor agonist lesogaberan (AZD3355) has been developed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy (partial responders). This study aimed to explore the dose-response effect of lesogaberan on reflux episodes in partial responders.
508. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
作者: Gregory J Dore.;Eric Lawitz.;Christophe Hézode.;Stephen D Shafran.;Alnoor Ramji.;Harvey A Tatum.;Gloria Taliani.;Albert Tran.;Maurizia R Brunetto.;Serena Zaltron.;Simone I Strasser.;Nina Weis.;Wayne Ghesquiere.;Samuel S Lee.;Dominique Larrey.;Stanislas Pol.;Hugh Harley.;Jacob George.;Scott K Fung.;Victor de Lédinghen.;Peggy Hagens.;Fiona McPhee.;Dennis Hernandez.;David Cohen.;Elizabeth Cooney.;Stephanie Noviello.;Eric A Hughes.
来源: Gastroenterology. 2015年148卷2期355-366.e1页
Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%-80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy.
509. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
作者: Frank A Sinicrope.;Qian Shi.;Thomas C Smyrk.;Stephen N Thibodeau.;Rodrigo Dienstmann.;Justin Guinney.;Brian M Bot.;Sabine Tejpar.;Mauro Delorenzi.;Richard M Goldberg.;Michelle Mahoney.;Daniel J Sargent.;Steven R Alberts.
来源: Gastroenterology. 2015年148卷1期88-99页
Categorization of colon cancers into distinct subtypes using a combination of pathway-based biomarkers could provide insight into stage-independent variability in outcomes.
510. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
作者: Michael Charlton.;Edward Gane.;Michael P Manns.;Robert S Brown.;Michael P Curry.;Paul Y Kwo.;Robert J Fontana.;Richard Gilroy.;Lewis Teperman.;Andrew J Muir.;John G McHutchison.;William T Symonds.;Diana Brainard.;Brian Kirby.;Hadas Dvory-Sobol.;Jill Denning.;Sarah Arterburn.;Didier Samuel.;Xavier Forns.;Norah A Terrault.
来源: Gastroenterology. 2015年148卷1期108-17页
Interferon alfa-based regimens used to treat recurrent hepatitis C virus (HCV) infection after liver transplantation are poorly tolerated, associated with generally modest efficacy, and can interact with immunosuppressive agents. We evaluated the efficacy and safety of an interferon-free regimen of the nucleotide polymerase inhibitor sofosbuvir combined with ribavirin for 24 weeks in treating post-transplantation HCV infection.
511. Symptom profile in partial responders to a proton pump inhibitor compared with treatment-naïve patients with gastroesophageal reflux disease: a post hoc analysis of two study populations.
Partial response to proton pump inhibitor (PPI) therapy poses a healthcare challenge. This study aimed to compare symptom profiles in partial PPI responders and treatment-naïve patients with gastroesophageal reflux disease (GERD).
512. Efficacy of transoral fundoplication for treatment of chronic gastroesophageal reflux disease incompletely controlled with high-dose proton-pump inhibitors therapy: a randomized, multicenter, open label, crossover study.
作者: Karim Sami Trad.;Gilbert Simoni.;William Edris Barnes.;Ahmad Bassel Shughoury.;Mamoon Raza.;Jeffrey Alan Heise.;Daniel Gilles Turgeon.;Mark Alan Fox.;Peter George Mavrelis.
来源: BMC Gastroenterol. 2014年14卷174页
The aim of this randomized, crossover study was to determine if transoral fundoplication (TF) could further improve clinical outcomes in partial responders to high-dose (HD) proton-pump inhibitor (PPI) therapy and to evaluate durability of TF.
513. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
作者: Michael P Curry.;Xavier Forns.;Raymond T Chung.;Norah A Terrault.;Robert Brown.;Jonathan M Fenkel.;Fredric Gordon.;Jacqueline O'Leary.;Alexander Kuo.;Thomas Schiano.;Gregory Everson.;Eugene Schiff.;Alex Befeler.;Edward Gane.;Sammy Saab.;John G McHutchison.;G Mani Subramanian.;William T Symonds.;Jill Denning.;Lindsay McNair.;Sarah Arterburn.;Evguenia Svarovskaia.;Dilip Moonka.;Nezam Afdhal.
来源: Gastroenterology. 2015年148卷1期100-107.e1页
Patients with detectable hepatitis C virus (HCV) RNA at the time of liver transplantation universally experience recurrent HCV infection. Antiviral treatment before transplantation can prevent HCV recurrence, but existing interferon-based regimens are poorly tolerated and are either ineffective or contraindicated in most patients. We performed a trial to determine whether sofosbuvir and ribavirin treatment before liver transplantation could prevent HCV recurrence afterward.
514. Prucalopride is no more effective than placebo for children with functional constipation.
作者: Suzanne M Mugie.;Bartosz Korczowski.;Piroska Bodi.;Alexandra Green.;René Kerstens.;Jannie Ausma.;Magnus Ruth.;Amy Levine.;Marc A Benninga.
来源: Gastroenterology. 2014年147卷6期1285-95.e1页
Prucalopride is a selective, high-affinity agonist of the 5-hydroxytryptamine (serotonin) receptor 4 that enhances motility in the gastrointestinal tract. We performed a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of prucalopride in children (6 months to 18 years old) with functional constipation.
515. Endoscopic nasobiliary drainage for obstructive jaundice using either a 5 Fr or 7 Fr catheter: a prospective, randomized trial.
作者: Toshio Fujisawa.;Koichi Kagawa.;Shunsuke Watanabe.;Kantaro Hisatomi.;Kensuke Kubota.;Hajime Sato.;Atsushi Nakajima.;Nobuyuki Matsuhashi.
来源: BMC Gastroenterol. 2014年14卷161页
The influence of size on the effectiveness of nasobiliary catheters has not yet been studied. We compared biliary drainage effectiveness and procedure-related discomfort and adverse events in 5 French (Fr) and 7 Fr nasobiliary catheters.
516. Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients.
作者: Khean Lee Goh.;Kee Don Choi.;Myung-Gyu Choi.;Tsai-Yuan Hsieh.;Hwoon-Yong Jung.;Han-Chung Lien.;Jayaram Menon.;Steven Mesenas.;Hyojin Park.;Bor-Shyang Sheu.;Justin Cy Wu.
来源: BMC Gastroenterol. 2014年14卷156页
Predicting response to proton pump inhibitor (PPI) treatment can aid the effective management of gastroesophageal reflux disease (GERD). The aim was to investigate the predictors of symptomatic response to pantoprazole in Asian patients with GERD; the first study of its kind in Asian patients.
517. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
作者: Omoniyi J Adedokun.;William J Sandborn.;Brian G Feagan.;Paul Rutgeerts.;Zhenhua Xu.;Colleen W Marano.;Jewel Johanns.;Honghui Zhou.;Hugh M Davis.;Freddy Cornillie.;Walter Reinisch.
来源: Gastroenterology. 2014年147卷6期1296-1307.e5页
We analyzed data collected during the Active Ulcerative Colitis Trials (ACT-1 and ACT-2) to assess relationships between serum concentrations of infliximab and outcomes of adults with moderate-to-severe ulcerative colitis.
518. Glucagon-like peptide-2 regulates release of chylomicrons from the intestine.
作者: Satya Dash.;Changting Xiao.;Cecilia Morgantini.;Philip W Connelly.;Bruce W Patterson.;Gary F Lewis.
来源: Gastroenterology. 2014年147卷6期1275-1284.e4页
The intestine efficiently incorporates and rapidly secretes dietary fat as chylomicrons (lipoprotein particles comprising triglycerides, phospholipids, cholesterol, and proteins) that contain the apolipoprotein isoform apoB-48. The gut can store lipids for many hours after their ingestion, and release them in chylomicrons in response to oral glucose, sham feeding, or unidentified stimuli. The gut hormone glucagon-like peptide-2 (GLP-2) facilitates intestinal absorption of lipids, but its role in chylomicron secretion in human beings is unknown.
519. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
作者: Enrique Quintero.;Marta Carrillo.;Antonio Z Gimeno-García.;Manuel Hernández-Guerra.;David Nicolás-Pérez.;Inmaculada Alonso-Abreu.;Maria Luisa Díez-Fuentes.;Víctor Abraira.
来源: Gastroenterology. 2014年147卷5期1021-30.e1; quiz e16-7页
Colonoscopy is the recommended screening procedure for first-degree relatives of patients with colorectal cancer (CRC), but few studies have compared its efficacy for CRC detection with that of other screening strategies. We conducted a controlled randomized trial to compare the efficacy of repeated fecal immunochemical tests (FITs) and colonoscopy in detecting advanced neoplasia (advanced adenoma or CRC) in family members of patients with CRC.
520. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome.
作者: Annette Fritscher-Ravens.;Detlef Schuppan.;Mark Ellrichmann.;Stefan Schoch.;Christoph Röcken.;Jochen Brasch.;Johannes Bethge.;Martina Böttner.;Julius Klose.;Peter J Milla.
来源: Gastroenterology. 2014年147卷5期1012-20.e4页
We investigated suspected food intolerances in patients with irritable bowel syndrome (IBS) using confocal laser endomicroscopy (CLE) for real-time visualization of structural/functional changes in the intestinal mucosa after food challenge. Patients with functional changes after food challenge (CLE+) were placed on personalized exclusion diets and followed up for long-term symptom relief.
|